TY - JOUR T1 - SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis DO - 10.1136/annrheumdis-2022-222512 SP - annrheumdis-2022-222512 AU - Enrique Morales AU - Maria Galindo Y1 - 2022/05/11 UR - http://ard.bmj.com/content/early/2022/05/12/annrheumdis-2022-222512.abstract N2 - Systemic lupus erythematosus (SLE) is a chronic autoimmune condition characterised by heterogeneous clinical features. The patients with SLE are known to have an increased risk of cardiovascular events, due to both traditional and disease-specific risk factors, including inflammation, endothelial dysfunction, accelerated atherosclerosis and lupus nephritis (LN). Since chronic kidney disease (CKD) is per se one of the strongest CV risk factors, any manoeuvres to prevent CKD progression, including reduction of albuminuria and prevention of estimated glomerular filtration decline, will likely have profound influences on patient outcomes.1 2All patients with LN have by definition CKD, since they display albuminuria to varying degrees. While albuminuria is a classical sign of renal damage, a substantial portion of patients will also have structural and functional impairment of their kidney function as hallmark of CKD, that is, glomerular hyperfiltration and albuminuria. In the past, renin–angiotensin–aldosterone system inhibitors (RAASi) has already conferred nephroprotective potential in patients with LN; however, a substantial residual renal risk remains … ER -